AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Submission of Matters to a Vote of Security Holders

AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item 5.07. Submission of Matters to a Vote of Security
Holders.

On May30, 2017, AveXis,Inc. (the Company) held its
Annual Meeting of Stockholders (the Annual Meeting).
As of April5, 2017, the record date for the Annual Meeting, there
were 27,743,174 shares of common stock outstanding and entitled
to vote. At the Annual Meeting, 23,789,219 shares, or
approximately 85.7% of the eligible voting shares, were
represented either in person or by proxy.

At the Annual Meeting, the Companys stockholders voted on the
following items:

1. Proposal 1: To elect two nominees to the board of directors to
hold office until the 2020 Annual Meeting of Stockholders and
until their respective successors are elected and qualified. The
following nominees were elected to the Companys board of
directors, with the voting results for each nominee as shown:

For

Withheld

Paul B. Manning

16,924,941

2,612,975

Sean P. Nolan

16,923,411

2,614,505

2. Proposal 2: To ratify the selection by the Audit Committee of
the Board of Directors of PricewaterhouseCoopersLLP as the
independent registered public accounting firm of the Company for
its fiscal year ending December31, 2017. This proposal was
approved by the votes indicated below:

For

Against

Abstain

23,783,417

3,173

2,629


About AVEXIS, INC. (NASDAQ:AVXS)

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

AVEXIS, INC. (NASDAQ:AVXS) Recent Trading Information

AVEXIS, INC. (NASDAQ:AVXS) closed its last trading session down -2.04 at 70.04 with 400,456 shares trading hands.

An ad to help with our costs